Printer Friendly

ADVANCED TISSUE SCIENCES AND KIRIN ENTER INTO AGREEMENT

 LA JOLLA, Calif., March 8 /PRNewswire/ -- Advanced Tissue Sciences, Inc. (NASDAQ-NMS: ATIS) and Kirin Brewery Company, Limited announced today that they have entered into an agreement to further develop a Stem Cell Proliferation Factor (SCPF) and grant to Kirin license options for the commercialization of SCPF and related technologies in Asia. Under this arrangement, Advanced Tissue Sciences could receive up to $29 million in payments for upfront fees, research funding and milestone payments. Another $10 million could be received by Advanced Tissue Sciences in connection with Kirin's exercise of its option to license certain additional technologies. Advanced Tissue Sciences would also receive royalties on SCPF product sales in Asia. SCPF is a novel growth factor for which Advanced Tissue Sciences recently obtained worldwide rights from the University of Florida Research Foundation, Inc.
 "We believe SCPF may be an important adjunct to our core tissue engineering business," said Arthur J. Benvenuto Advanced Tissue Sciences' chairman, president and chief executive officer. "This collaboration will allow us to further the development of SCPF without diverting our focus from Dermagraft(TM) and our In Vitro Laboratory Testing business. In addition, the payments we receive will enable us to accelerate the development of our future tissue engineered products."
 Under the license options, Kirin would obtain exclusive rights to SCPF in Asia including its use in the proliferation of hematopoietic stem cells. In addition, Kirin receives options to license other technologies, including Advanced Tissue Sciences' bone marrow culture technology in Asia. Advanced Tissue Sciences will retain exclusive rights to SCPF for the rest of the world, as well as rights to use SCPF in all tissue engineering applications worldwide.
 Data on this novel growth factor was first announced at the American Society of Hematology (ASH) meeting last December showing that SCPF stimulates the growth of hematopoietic stem cells, the cells responsible for repopulating the immune system. Advanced Tissue Sciences' collaborators have shown that SCPF may be used to reconstitute cell populations that frequently are destroyed by chemotherapy or radiation therapy. SCPF could potentially have applications in bone marrow transplants, the treatment of chemotherapy patients and a variety of blood cell disorders.
 An update on SCPF research will be presented in San Diego on March 12, 1993, at a hematology meeting sponsored by the University of California at San Diego School of Medicine.
 "We chose Kirin for this partnership because of their strong reputation, expertise and their proven success in Japan with erythropoietin (EPO) and G-CSF which Kirin developed through a collaboration with Amgen," said Dr. Gail K. Naughton, Advanced Tissue Sciences' executive vice president and chief operating officer. "By entering into this agreement, Advanced Tissue Sciences not only obtains an experienced partner in Japan, but also a source of supply of SCPF that could prove to be important in the manufacturing of future tissue engineered products such as bone marrow, gastrointestinal tract and liver."
 "We are very pleased to be entering into this partnership with Advanced Tissue Sciences," said Dr. Toru Sasahara, president of Kirin's pharmaceuticals division. "We believe that further research with SCPF may lead to the development of many potentially important therapeutic products in Asia. Entering into this collaboration furthers our position as a leader in hemaotopoietic growth factors."
 Kirin Brewery Company is one of the leading companies developing biopharmaceutical products in Japan. Kirin currently markets erythropoietin under the brand name ESPO in Japan and granulocyte macrophage colony stimulation factor under the brand name GRAN in Asia.
 Advanced Tissue Sciences is a tissue engineering company engaged in the growth of human tissues and organs for potential therapeutic and laboratory applications. Using its proprietary three-dimensional culture system, the company has successfully replicated a variety of human tissues including skin, cartilage, oral mucosa, bone marrow, and liver.
 -0- 3/8/93
 /CONTACT: Janet Wahl, director, corporate communications of Advanced Tissue Sciences, 619-450-5737/
 (ATIS)


CO: Advanced Tissue Sciences, Inc.; Kirin Brewery Company, Ltd. ST: California IN: MTC SU:

PS -- NY012 -- 3771 03/08/93 07:31 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 8, 1993
Words:660
Previous Article:MARGARETTEN FINANCIAL REPORTS FEBRUARY SOURCES OF PRODUCTION AND LOAN APPLICATION ACTIVITY; ANNOUNCES ANNUAL MEETING DATE
Next Article:TI RESOLVES ALL PC SYSTEM LITIGATION; DAEWOO AND DELL SIGN LICENSING AGREEMENTS
Topics:


Related Articles
ADVANCED TISSUE SCIENCES AND NEOMORPHICS SIGN DEFINITIVE ACQUISITION AGREEMENT
ADVANCED TISSUE SCIENCES INC. REPORTS 1992 RESULTS
ADVANCED TISSUE SCIENCES INC. REPORTS FIRST QUARTER RESULTS
ADVANCED TISSUE SCIENCES INC. REPORTS SECOND QUARTER RESULTS
ADVANCED TISSUE SCIENCES INC. REPORTS THIRD QUARTER RESULTS
ADVANCED TISSUE SCIENCES OBTAINS $50 MILLION EQUITY LINE
Dermagraft(R) Shows Statistical Significance in The Treatment of Diabetic Foot Ulcers; PMA To Be Submitted in December
Osiris Therapeutics Completes License and Research Agreement with Northwestern University for a Novel Cartilage-Forming Molecule
Advanced Tissue Sciences Announces Submission of Premarket Approval Application for Dermagraft(R) in Diabetic Foot Ulcers
Advanced Tissue Sciences Announces Submission of Premarket Approval Application for Dermagraft(R) in Diabetic Foot Ulcers

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters